AB 2188 Cannabis Job Discrimination Law — What Employers Must Know

Most employers assume legal cannabis means recreational use is protected at work. AB 2188 clarifies something more nuanced: California employers cannot take adverse action against employees based on off-duty cannabis use. But only when detected through non-psychoactive metabolite testing. The law went into effect January 1, 2024, and applies to nearly all California employers with limited exemptions for federal contractors, building trades covered by collective bargaining agreements, and positions requiring federal background clearances. The distinction between psychoactive THC and non-psychoactive metabolites is the operational hinge. Standard urine tests detect THC-COOH, a metabolite that persists 30+ days after use while indicating zero current impairment.

Our team has reviewed compliance frameworks for hundreds of California businesses navigating AB 2188 implementation. Employers who misunderstand the metabolite distinction face significant legal exposure. Not from permitting workplace impairment, but from penalising employees for legal off-duty conduct detected through testing methods the law now restricts.

What does AB 2188 cannabis job discrimination law mean for California employers?

AB 2188 prohibits California employers from discriminating against job applicants or employees based on off-duty cannabis use or non-psychoactive cannabis metabolites found in drug screening results. Effective January 2024, employers cannot refuse to hire, terminate, or otherwise penalize workers solely because a drug test detected THC-COOH. The inactive metabolite standard urine tests identify. The law does not protect on-duty use, workplace possession, or impairment during work hours, and exemptions apply to federal contractors, certain unionised building trades, and federally regulated positions.

AB 2188 does not legalise workplace cannabis use. That remains grounds for termination under every California employer policy. What changed is the evidentiary standard: employers can no longer rely on metabolite presence alone as proof of policy violation. A positive urine test result that would have justified termination in December 2023 now requires additional evidence of actual impairment or on-duty use to support the same employment action in 2026. This article covers the law's precise scope and exemptions, compliant testing alternatives, the distinction between psychoactive and non-psychoactive compounds that determines legal exposure, and operational adjustments that align existing drug-free workplace policies with AB 2188 requirements without compromising safety protocols.

The Scope and Exemptions of AB 2188 Cannabis Job Discrimination Protections

AB 2188 applies to all California employers regardless of size. Single-employee businesses and multinational corporations face identical obligations. The law amends California Government Code Section 12954 to add cannabis-related discrimination as an unlawful employment practice under the Fair Employment and Housing Act (FEHA). Coverage includes hiring decisions, promotion eligibility, disciplinary actions, and termination. Any adverse employment action predicated solely on off-duty cannabis use or non-psychoactive metabolite detection violates the statute. The effective date of January 1, 2024 means employment decisions made after that date using pre-2024 test results still fall under AB 2188 scrutiny if those results reflect only metabolite presence.

Three exemptions carve out specific employment categories. First, employers required to conduct drug testing under federal law or regulation. Including Department of Transportation (DOT) regulated positions, federal contractors subject to Drug-Free Workplace Act requirements, and employers receiving federal grants or contracts with mandatory drug testing clauses. Remain exempt from AB 2188 restrictions. Second, building and construction trades employees covered by collective bargaining agreements with drug testing provisions negotiated before January 1, 2024 are temporarily exempt, though renegotiated agreements must comply. Third, positions requiring federal security clearances or background investigations continue to permit cannabis-based exclusions regardless of AB 2188. The exemptions are narrow. An employer with one DOT-regulated driver cannot apply DOT testing standards to administrative staff, and federal contractor status applies only to employees directly performing federal contract work.

The law explicitly preserves employer rights to maintain drug-free workplace policies, discipline employees for on-duty impairment, and prohibit workplace possession or use. AB 2188 addresses only the evidentiary basis for employment actions. Not the conduct itself. An employer can terminate an employee who arrives at work impaired, possesses cannabis on company property, or uses cannabis during work hours. The same employer cannot terminate an employee solely because a urine test detected THC-COOH from weekend use three weeks prior. This distinction reshapes compliance requirements for employers who previously treated any positive cannabis test result as automatic grounds for termination.

Psychoactive THC vs Non-Psychoactive Metabolites — The Legal Distinction That Determines Compliance

AB 2188's enforceability hinges on the biological difference between delta-9-tetrahydrocannabinol (THC). The psychoactive compound that causes impairment. And THC-COOH (11-nor-9-carboxy-THC), the non-psychoactive metabolite standard urine tests detect. THC remains detectable in blood and saliva for 3–12 hours post-consumption in most users, corresponding to the window of actual cognitive and motor impairment. THC-COOH persists in urine for 30+ days after a single use in regular consumers, and detection indicates only prior exposure. Not current impairment, recent use, or frequency of use. The metabolic pathway is straightforward: THC is broken down by the liver into 11-OH-THC (still psychoactive), which further metabolises into THC-COOH (non-psychoactive), which is stored in fat cells and released slowly into urine over weeks.

Standard workplace urine drug screens. The immunoassay tests used by 90%+ of California employers pre-AB 2188. Detect THC-COOH exclusively. These tests do not and cannot measure THC itself or determine impairment status. A positive urine test at 50 ng/mL (the federal cutoff) or 20 ng/mL (common private employer cutoff) confirms only that the individual consumed cannabis at some point in the prior 1–30+ days depending on usage frequency and metabolism. AB 2188 prohibits adverse employment actions based on this metabolite detection because it provides no evidence of workplace impairment or on-duty use. Employers who continue using urine tests as the sole basis for cannabis-related terminations face FEHA violation claims regardless of policy language.

Compliant testing alternatives fall into two categories. Oral fluid (saliva) testing detects THC itself rather than metabolites, with a detection window of 4–12 hours that corresponds more closely to impairment duration. Blood testing also detects active THC, though the invasiveness and cost make it impractical for routine workplace screening. Employers concerned about workplace impairment now face a testing technology decision: continue urine screening and accept that positive cannabis results cannot independently support employment actions under AB 2188, or transition to oral fluid testing that detects recent use within the impairment window. Neither option is perfect. Oral fluid testing costs 30–50% more than urine panels and has lower sensitivity for other drug classes. Our team has found that most employers in safety-sensitive industries are piloting oral fluid panels for cannabis while maintaining urine tests for other substances, creating a hybrid protocol that balances cost and compliance.

AB 2188 Cannabis Job Discrimination Law: Employment Testing Comparison

Key Takeaways

• AB 2188 prohibits California employers from discriminating against employees based on off-duty cannabis use or non-psychoactive metabolite detection starting January 1, 2024.
• Standard urine drug tests detect THC-COOH. A non-psychoactive metabolite that persists 30+ days after use. And cannot serve as the sole basis for adverse employment actions under the law.
• Employers retain full authority to prohibit on-duty impairment, workplace possession, and cannabis use during work hours. AB 2188 restricts only the evidentiary use of metabolite test results.
• Federal contractors, certain unionised building trades with pre-2024 collective bargaining agreements, and positions requiring federal clearances remain exempt from AB 2188 restrictions.
• Oral fluid testing detects active THC within a 4–12 hour window correlating to impairment and represents the most viable compliant testing alternative for safety-sensitive employers.
• Employers who continue using urine tests must pair positive cannabis results with additional evidence of impairment or policy violation (supervisor observations, performance issues, on-duty conduct) to support disciplinary actions.

What If: AB 2188 Cannabis Job Discrimination Scenarios

What If an Employee Tests Positive for Cannabis Metabolites After a Workplace Accident?

Document all observable impairment indicators independently of the test result. AB 2188 does not prevent post-accident drug testing. It prevents using metabolite-only results as proof of causation. If the employee exhibited slurred speech, coordination issues, confusion, or other impairment signs witnessed and documented by supervisors before testing, those observations support a policy violation finding. If no impairment was observed and the urine test simply detected THC-COOH from off-duty use days or weeks prior, AB 2188 prohibits disciplinary action based on the test alone. Employers in this scenario should conduct a thorough accident investigation documenting all contributing factors. Equipment failure, procedural non-compliance, environmental conditions. And make employment decisions based on the totality of evidence rather than test results in isolation.

What If We Have a Zero-Tolerance Drug Policy That Pre-Dates AB 2188?

Update policy language to distinguish between prohibited conduct and testing evidence. A zero-tolerance policy can still prohibit on-duty impairment, workplace possession, and cannabis use during work hours. AB 2188 does not require employers to permit those behaviours. What requires revision is any policy language that treats a positive drug test result as automatic grounds for termination without regard to the compound detected or the timeframe of use. Replace 'any positive drug test result' with 'detection of psychoactive substances indicating on-duty use or current impairment' or similar language that aligns with AB 2188's metabolite distinction. Employers who terminate employees under pre-2024 policy language after January 1, 2024 face retroactive FEHA claims if the only evidence was metabolite detection.

What If an Applicant Tests Positive During Pre-Employment Screening?

Pre-employment testing falls under AB 2188 equally with post-hire testing. Refusing to hire an applicant based solely on THC-COOH detection in a urine test violates the statute. Employers can require pre-employment drug screening and can refuse to hire applicants who test positive for other controlled substances or for active THC detected through oral fluid testing. The law does not require employers to hire cannabis users. It prohibits using non-psychoactive metabolite presence as the basis for hiring decisions. Transition pre-employment panels to oral fluid testing if cannabis screening remains an employment criterion, or remove cannabis from pre-employment panels entirely and rely on supervisor training to identify and address on-duty impairment post-hire.

What If the Employee Works in a Safety-Sensitive Position Like Equipment Operation or Transportation?

Safety-sensitive designation does not exempt employers from AB 2188 unless the position falls under federal DOT regulations or similar statutory exemptions. California law does not recognise a blanket 'safety-sensitive' exception. Employers must demonstrate that the specific position meets one of the three statutory exemptions (federal testing mandate, collective bargaining agreement, federal clearance requirement). For non-exempt safety-sensitive roles, employers can enforce stricter conduct policies. Prohibiting any detectable impairment, requiring fitness-for-duty evaluations, implementing reasonable suspicion testing protocols. But cannot use urine metabolite results as standalone proof of policy violation. Oral fluid testing offers the most defensible approach for safety-sensitive employers outside federal exemptions, as the detection window aligns with the period of actual impairment risk.

The Unvarnished Truth About AB 2188 Employer Compliance

Here's the honest answer: AB 2188 implementation exposes how many California employers were using drug testing as a conduct proxy rather than an impairment detection tool. Urine tests were never designed to measure workplace impairment. They measure past exposure, which employers treated as sufficient evidence of policy violation because it was administratively simple and legally defensible pre-2024. The law forces employers to distinguish between 'this employee used cannabis at some point in the past month' and 'this employee was impaired at work'. And that distinction requires supervisor observation, documentation, and judgment that many workplace drug policies were designed to avoid. Employers who frame AB 2188 as 'we can no longer test for cannabis' misunderstand the law. You can test, but metabolite results no longer carry the evidentiary weight they did before January 2024, and relying on them alone creates FEHA liability.

The operational challenge is not the law's requirements. It is retrofitting workplace safety protocols that depended on objective test results to now incorporate subjective impairment assessment. Training supervisors to recognise and document impairment indicators, establishing clear reasonable suspicion testing triggers, and pairing test results with observational evidence are not new concepts. They are the standard in alcohol impairment cases and have been for decades. Cannabis presents a pharmacokinetic complication (metabolite persistence) that alcohol does not, but the managerial framework is identical. Employers unwilling to invest in that training and documentation infrastructure will find AB 2188 compliance operationally difficult; employers who build robust impairment detection protocols will find the law changes very little about day-to-day workplace management. The statute did not weaken employer authority to maintain safe, drug-free workplaces. It clarified that metabolite presence is not evidence of workplace impairment, which was always scientifically accurate even when legally irrelevant.

Our commitment to transparency extends across every aspect of cannabis compliance and access. Explore how Seaweed Delivery approaches product quality, compliance verification, and customer education at a standard most providers avoid because it requires work they are unwilling to do.

AB 2188 cannabis job discrimination law represents the legal system catching up to the scientific reality that THC-COOH detection in urine reveals nothing about current impairment or recent use. Employers who treated positive cannabis tests as automatic violations were operationally efficient but scientifically wrong. The law now requires alignment between testing methods and the employment decisions they support. The adjustment is not optional, and the liability for non-compliance is material. FEHA violations carry uncapped compensatory damages, punitive damages in cases of malice or reckgard, and attorney fee awards that make even single-plaintiff cases expensive to defend. Employers who understand the metabolite distinction, update policies accordingly, and train supervisors on impairment recognition will navigate AB 2188 without operational disruption. Those who continue terminating employees based on urine test results alone will spend the next several years in litigation that existing case law now strongly favours the employee.